拉科萨米德在帕金森病的小鼠模型中表现出神经保护作用
Burcin Bilal1, Mehmet Kirazlar1, Mumin Alper Erdogan1
1Izmir Katip Celebi University, Faculty of Medicine, Department of Physiology, Izmir, Turkey.
Journal of chemical neuroanatomy
|July 13, 2023
概括
抗药物拉科萨米德在帕金森病 (PD) 的大鼠模型中表现出神经保护作用. 这项研究发现,lacosamide减少了神经炎症,并保留了多巴胺类神经元,这表明PD的潜在治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,影响运动功能,目前没有治愈方法.
- 拉科萨米德是一种抗药物,在初步研究中显示出潜在的神经保护性质.
- 这项研究研究了lacosamide在 PD 的动物模型中的神经保护作用.
研究的目的:
- 为了评估lacosamide的神经保护功效,在一个由rotenone诱导的帕金森病的老鼠模型中.
- 评估拉科萨米德对运动功能的影响,多巴胺基神经元存活率和神经退行症的生化标志物.
主要方法:
- 在成年雄性大鼠中建立了罗农诱导的帕金森病模型.
- 鼠被分为载体,罗诺和罗诺 + 拉科萨米德治疗组.
- 通过阿波莫芬诱导的旋转测试来评估运动功能;通过免疫组织化学和特定标记物的生物化学分析来评估神经保护.
主要成果:
- 拉科萨米德治疗显著降低了马隆迪阿尔海德和TNF-α的水平,同时增加了罗诺治疗的老鼠的HVA水平.
- 拉科萨米德的使用改善了运动功能,这是由较低的阿波莫尔芬诱导的旋转得分所表明的.
- 在接受了lacosamide治疗的老鼠中,观察到黑色物质中多巴氨基神经元的显著保存和氨酸氧酶 (TH) 免疫光度的增加.
结论:
- 拉科萨米德在帕金森病的小鼠模型中表现出显著的神经保护作用.
- 这些发现表明,lacosamide可能有助于维护多巴胺能神经元功能并减轻神经炎症.
- 需要进一步的研究来阐明机制,并探索lacosamide在PD治疗中的临床潜力.
相关概念视频
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
349
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
349


